Similarly, BELLE-3 was designed to include Luminal A (HR+/HER-) breast cancer patients that had been previously unsuccessfully treated by prior endocrine therapy and mTOR inhibitors [68]. The gene discussed is MTOR; the disease is breast carcinoma.